EMA and Swissmedic agree on further Cooperation
The European Medicines Agency (EMA), the Directorate General Health and Food Safety (DG SANTE) of the European Commission and the Swissmedic signed an agreement which aims at ensuring a better exchange of non-public information for the protection of the public health. It is intended to exchange information related to the safety, quality or efficacy of medicines which are either already approved or in the authorisation process in the EU or in Switzerland. A similar agreement existed in 2009/2010 at the time of the H1N1 pandemic. The new agreement has been effective since the 10 July 2015 and will be valid for five years.
To find out more please see the original note on the page of the Swissmedic.
Related GMP News
02.10.2024MHRA: New Rules for Manufacturers and Wholesalers after Brexit
24.09.2024What is RCA (Root Cause Analysis)?
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)
04.09.2024Insufficient Root Cause Analysis leads to FDA Warning Letter
28.08.2024Switzerland to implement Measures to combat Shortages of Medicines